ArticleEuroasian journal of hepato-gastroenterology
Incidence and Characterization of SIBO in NAFLD Patients.
Article in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The correlation between small intestinal bacterial overgrowth (SIBO) and nonalcoholic fatty liver disease (NAFLD) has gained heightened acknowledgment, especially in the late phases of liver disease. Despite this, studies focusing on the prevalence and specific characteristics of SIBO within the steatotic liver disease patient population in Pakistan remain sparse. This research seeks to investigate the prevalence and characteristics of SIBO in patients with fatty liver disease in a tertiary healthcare facility in Karachi. Materials and methods: Conducted from July 2023 to March 2024 at Ziauddin Medical University Hospital's Clifton Campus, this prospective cross-sectional study included 65 adults aged 18-80 diagnosed with NAFLD via FibroScan®. The evaluation of small bowel microbial overgrowth was established by a glucose hydrogen breath test (GHBT), where a rise in hydrogen concentration of ≥20 ppm from the initial measurement within two hours signifies a good outcome. Participant demographics, comorbid conditions, and clinical symptoms were documented. Results: Of the 65 individuals, 46 were male, with an average age of 44.88 ± 12.30 years, a mean index of body mass of 26.45 ± 6.45 kg/m², and an average waist measurement of 95.20 ± 15.17 cm. Lean NAFLD was observed in 40% of the participants. Frequent comorbidities included diabetes (40%), hypertension (38%), and dyslipidemia (38%). Small intestinal bacterial overgrowth was identified in 37% of the subjects, 28% of whom were asymptomatic. Symptoms prevalent in SIBO-positive individuals were bloating (41%), belching (26%), and abdominal pain (28%). Liver stiffness indicated that 23% had F2 fibrosis, 28% had F3, and 49% had F4. Controlled attenuation parameter (CAP) scores showed S1 steatosis in 37% of patients, S2 in 29%, and S3 in 34%. The presence of SIBO correlated with increasing fibrosis and steatosis levels. Small intestinal bacterial overgrowth (SIBO) positivity was more prevalent in the high Child-Pugh class and more severe liver dysfunction. With post-treatment giving Conclusion: This research highlights a significant incidence of SIBO in NAFLD individuals, particularly those with severe liver damage and comorbidities. It stresses the importance of regular screening for SIBO in such patients, suggesting that timely detection and intervention could enhance patient outcomes. How to cite this article: Naizr S, Abbas Z, Gazder DP,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.